<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03272269</url>
  </required_header>
  <id_info>
    <org_study_id>IMCY-T1D-001</org_study_id>
    <nct_id>NCT03272269</nct_id>
  </id_info>
  <brief_title>Study of IMCY-0098 in Patients With Recent Onset Type 1 Diabetes</brief_title>
  <official_title>A Phase I Placebo-controlled, Double-blind, Dose Escalation Clinical Trial to Evaluate the Safety and Immune Responses of Imcyse's IMCY-0098 in Patients With Recent Onset Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imcyse SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imcyse SA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will evaluate the safety of an innovative approach expected to be
      disease-modifying by stopping the auto-immune-mediated destruction of islet β-cells in the
      pancreas. Three doses of the investigational product will be tested in successive cohorts.
      Although safety is the first objective of this study, we will gather efficacy data and
      perform a set of immunological tests to further understand the mechanism of action of this
      new approach in young adults with recent onset type 1 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 23, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-blind, placebo controlled</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all adverse events reported for subjects</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Safety assessed through measurement and comparison of any reactions or hypersensitivity to IMCY-0098 injection vs placebo. Number of adverse events will also be compared between groups with the addition of safety monitoring blood tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of residual beta cell function and markers of metabolic control</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Measured by a change in stimulated C-peptide production, daily insulin usage, glycated haemoglobin levels and glucose levels and excursions from baseline and between groups</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Assessment of T lymphocyte immune response to IMCY-0098</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>Comparison of changes in IMCY-0098 specific T lymphocyte responses longitudinally following peptide treatment and versus placebo.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Cohort 1, low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 SC injections of IMCY-0098 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2, medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 SC injections of IMCY-0098 or Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3, high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 SC injections of IMCY-0098 or Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMCY-0098</intervention_name>
    <description>Small synthetic peptide for SC admin. Solvent: alum hydroxide</description>
    <arm_group_label>Cohort 1, low dose</arm_group_label>
    <arm_group_label>Cohort 2, medium dose</arm_group_label>
    <arm_group_label>Cohort 3, high dose</arm_group_label>
    <other_name>Imotope</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Solvent: alum hydroxide</description>
    <arm_group_label>Cohort 1, low dose</arm_group_label>
    <arm_group_label>Cohort 2, medium dose</arm_group_label>
    <arm_group_label>Cohort 3, high dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female 18 to 30 years of age

          2. Initial diagnosis of Type 1 diabetes according to ADA/WHO criteria within the past 6
             months

          3. Insulin requirement, as determined by the investigator

          4. Presence of at least one autoantibody (GAD65, IA-2, or ZnT8)

          5. Fasting C-peptide at screening &gt;0.2 nmol/L

          6. HLADR3-positive and/or HLADR4-positive

          7. Willingness to undergo the insulin treatment prescribed by the physician

          8. Body mass index (BMI) between 17-28 kg/m2 at screening

          9. Fully informed written consent obtained

         10. Males with reproductive potential should use barrier method of contraception (condom)
             from screening up to 90 days after last treatment with investigational product.

         11. Women of childbearing potential should use an highly effective contraception method
             from screening and for the whole duration of the study.

        Exclusion Criteria:

          1. Ongoing or planned pregnancy during the whole duration of the study or lactation

          2. Presence of significant medical conditions in particular chronic liver condition,
             chronic hematological disease, renal dysfunction of grade 2 or more according to the
             World Health Organization (WHO) Toxicity Scale .

          3. Has any current signs or symptoms of infection at entry or within 2 weeks of entry or
             has received intravenous antibiotics within 2 months prior to the first planned
             administration of the study product

          4. Has received any live, attenuated vaccine within 3 months prior to the first planned
             administration of the study product (i.e. oral poliomyelitis vaccine,
             measles-mumps-rubella vaccine, yellow fever vaccine, Japanese encephalitis vaccine,
             dengue vaccine, rotavirus vaccine, varicella vaccine, live-attenuated zoster vaccine,
             Bacillus Calmette-Guérin [BCG] vaccine, oral typhoid vaccine)

          5. History of, or current malignancy (except excised basal cell skin cancer)

          6. Clinical evidence of a diabetes-related complication that could interfere with
             patient's participation/completion of study

          7. Primary or secondary immune deficiency disorders

          8. Human Immunodeficiency virus (HIV), chronic hepatitis B virus (HBV) or hepatitis C
             virus (HCV) infection

          9. Presence at screening of abnormal laboratory values grade 2 or more according to the
             World Health Organization (WHO) Toxicity Scale

         10. Anti-diabetic treatments other than insulin in the week prior to first study drug
             administration

         11. Ongoing treatment with immunosuppressive agents or treatment within the past year with
             the exception of topical or intra nasal corticosteroids.

         12. Treatment with immunotherapy within the past 3 months

         13. Treatment with an investigational drug within the past 3 months

         14. Patients with a known hypersensitivity to any component of the drug product should be
             excluded from the study

         15. Patients under treatment with statins at the time of screening.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pierre Vandepapelière, MD</last_name>
    <role>Study Director</role>
    <affiliation>Imcyse SA</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Christian Boitard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Cochin, Paris, France</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pierre Vandepapelière, MD</last_name>
    <phone>0032 4 366 47 63</phone>
    <email>p.vandepapeliere@imcyse.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jean Van Rampelbergh, PhD</last_name>
    <email>j.vanrampelbergh@imcyse.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Erasme</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Brussel</name>
      <address>
        <city>Brussels</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bispebjerg and Frederiksberg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes, Hôpital Laennec</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint-Louis</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>GWT-TUD GmbH</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Justus-Liebig-Universität Gießen</name>
      <address>
        <city>Gießen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH)</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Cardiff University</name>
      <address>
        <city>Cardiff</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Devon and Exeter NHS Trust</name>
      <address>
        <city>Exeter</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Guy's and St. Thomas NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St. Bartholomew's Hospital (Barts Health NHS Trust)</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Newcastle University</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oxford University Hospitals NHS Foundation Trust</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.imcyse.com/en</url>
    <description>Sponsor website</description>
  </link>
  <link>
    <url>http://www.bdronline.be/index.php?n=169&amp;id=267&amp;sid=267&amp;taal=F&amp;mnav=2</url>
    <description>Registre belge du diabète</description>
  </link>
  <link>
    <url>http://www.bdronline.be/index.php?n=164&amp;id=265&amp;sid=265&amp;taal=N&amp;mnav=2</url>
    <description>Belgisch diabetes register</description>
  </link>
  <link>
    <url>http://www.address2.org/t1d-studies/</url>
    <description>Research study for people with Type 1 Diabetes: EXALT</description>
  </link>
  <link>
    <url>https://www.type1diabetesresearch.org.uk/current-trials/</url>
    <description>Research study for people with Type 1 Diabetes: EXALT</description>
  </link>
  <reference>
    <citation>Carlier VA, VanderElst L, Janssens W, Jacquemin MG, Saint-Remy JM. Increased synapse formation obtained by T cell epitopes containing a CxxC motif in flanking residues convert CD4+ T cells into cytolytic effectors. PLoS One. 2012;7(10):e45366. doi: 10.1371/journal.pone.0045366. Epub 2012 Oct 9.</citation>
    <PMID>23056200</PMID>
  </reference>
  <reference>
    <citation>Malek Abrahimians E, Carlier VA, Vander Elst L, Saint-Remy JM. MHC Class II-Restricted Epitopes Containing an Oxidoreductase Activity Prompt CD4(+) T Cells with Apoptosis-Inducing Properties. Front Immunol. 2015 Sep 2;6:449. doi: 10.3389/fimmu.2015.00449. eCollection 2015. Review.</citation>
    <PMID>26388872</PMID>
  </reference>
  <reference>
    <citation>Malek Abrahimians E, Vander Elst L, Carlier VA, Saint-Remy JM. Thioreductase-Containing Epitopes Inhibit the Development of Type 1 Diabetes in the NOD Mouse Model. Front Immunol. 2016 Mar 2;7:67. doi: 10.3389/fimmu.2016.00067. eCollection 2016.</citation>
    <PMID>26973647</PMID>
  </reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2017</study_first_submitted>
  <study_first_submitted_qc>September 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2017</study_first_posted>
  <last_update_submitted>November 9, 2017</last_update_submitted>
  <last_update_submitted_qc>November 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetes Mellitus type 1</keyword>
  <keyword>Autoimmune disease</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>Diabetes treatment</keyword>
  <keyword>Residual beta cell function</keyword>
  <keyword>Adult patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

